Free EHR, EHR and Healthcare IT Newsletter Want to receive the latest updates on EHR, EMR and Healthcare IT news sent straight to your email? Get all the latest EHR News for FREE!

Hg Invests in Orion Health Rhapsody and Population Health Businesses

BOSTON, Massachusetts – 6 July 2018 – Orion Health Group Limited (NZX:OHE/ASX:OHE) announced that it has reached an agreement in relation to Orion Health’s Rhapsody and Population Health businesses with Hg, a specialist technology investor committed to helping build global businesses with funds of c.£10 billion under management.

The agreement is for entities managed by Hg to acquire majority ownership of Orion Health’s Rhapsody business and to invest in Orion Health’s Population Health business.

Healthcare technology is a core investment area for Hg, having recently completed a number of transactions across the sector. This investment will be made from Hg’s Mercury 2 Fund.

Orion Health built the first Rhapsody integration engine in the late-1990s quickly becoming one of the most recognized interoperability platforms for healthcare organizations today. The combination of Rhapsody’s global team and Hg’s resources will extend Rhapsody as a leader in the interoperability platform space, building on both Rhapsody’s world class technology and highly rated customer service.

Philippe Houssiau, an experienced global technology executive, will step in to lead the Rhapsody business. Philippe has broad experience in leading healthcare businesses, consulting and start-ups, and is formerly CEO of Agfa Healthcare, CEO of Alliance Medical and a Senior Partner with PwC.

“This investment provides Orion Health with a tremendous opportunity to deliver on our vision for customers, our people and for the healthcare sector,” said Ian McCrae, Founder and CEO, Orion Health. “The Board and I believe that Hg is the right partner to accelerate the expansion of Rhapsody and support our vision for our Population Health business.”

“Hg has been researching the theme of interoperability and population health management in healthcare IT over many years,” said David Issott, Partner, Hg. “We believe this is a key global growth theme backed by substantial market funding and resources. Rhapsody provides fantastic products and services for this market and we look forward to partnering with the team at Rhapsody to maximize its potential across the globe. We are also excited to work with Ian and the team to realize the full potential of the Population Health business.”

“Rhapsody is a high-quality business with strong underlying fundamentals and a solid pipeline of new business,” said Philippe Houssiau, CEO Rhapsody. “We believe that the current healthcare market dynamic, with increasing requirement for ‘data liquidity’, presents Rhapsody with a real opportunity for further growth and a solid base for sustained performance. With a focused leadership team and the investment provided by Hg, Rhapsody will be able to leverage its core markets whilst expanding into selected and emerging segments.”

Full details of the transaction can be found in a Market Release on the investor page of Orion Health’s website here. Summary:

–          Hg will acquire Rhapsody for NZ$205 million funded by debt and equity arranged by Hg. Orion Health will then utilize circa NZ$28 million of the transaction proceeds to acquire an ongoing 24.9% shareholding in the Rhapsody business.

–          Hg will also acquire a 24.9% stake in Population Health by investing circa NZ$20 million in that business. Orion Health will invest around NZ$12 million of the Rhapsody transaction proceeds in Population Health based on an agreed enterprise value of NZ$50 million (on a cash free and debt free basis) together with NZ$30 million of net cash to fund ongoing operations.

–          Orion Health will continue to own 100% of its Hospitals business.

–          Following completion of the Hg Transaction, Orion Health will undertake a share buyback offer at an estimated price range of $1.24-$1.29 per share, with the final offer price dependent on Orion Health’s available cash immediately following completion taking into account transaction costs and working capital adjustments in relation to the Rhapsody transaction. Shareholders will have the option to accept the share buyback offer in respect of all or a specified proportion of their Orion Health shares.

–          The bottom of the estimated buy back price range represents a premium of 46% to the closing price per Orion Health share of $0.85 on 2 July 2018 and 55% to the volume weighted average trading price over the last 20 trading days.

The injection of capital will provide investment for Orion Health to build leading global technology for the healthcare sector.

“As the healthcare sector evolves, so too has Orion Health. We believe the biggest advances in healthcare technology will come from a range of capabilities including advanced analytics and better data flow to address critical issues within the sector. In the face of growing and aging populations and the rise of chronic diseases, health systems the world over are under enormous strain. Our Population Health and Hospitals solutions are focused on helping healthcare organizations turn data into insights and clinical action and allow them to use this knowledge to optimize budgets and provide targeted patient care.

“This injection of capital will advance Orion Health’s businesses to reach their full potential over time. For our Population Health business, it will help strengthen our position as a market leader, and for our Hospitals business, it will further support its growth,” said McCrae.

The transaction is subject to a number of conditions, including regulatory approval and the share buyback offer by Orion Health’s shareholders. A notice of meeting describing the Hg Transaction and the share buyback offer will be circulated to shareholders. The independent directors have also commissioned an independent report from KordaMentha.

“This transaction is an important stepping stone in Orion Health’s efforts to build a solid and competitive business and provides our shareholders with choice in relation to their investment,” said Andrew Ferrier, Chairman of the Board, Orion Health. “We believe that providing shareholders both the option to cash-out at a substantial premium to the current trading price and the opportunity to elect to maintain an ongoing investment in Orion Health, including its 24.9% stake in Rhapsody and 75.1% stake in Population Health, is in the best interests of shareholders. This transaction has strong support from Orion Health’s Board and major shareholders.”

About Orion Health
Orion Health (NZX:OHE/ASX:OHE) is a health technology company that provides solutions which enable healthcare to over 110 million patients globally. Its open technology platform, Orion Health Amadeus, seamlessly integrates all forms of relevant data to enable population and personalized healthcare around the world. The company is committed to continual innovation to cement its position at the forefront of precision medicine. For more information visit www.orionhealth.com.

About Hg
Hg is a sector expert investor, committed to helping build ambitious businesses across the technology, services and industrial technology space, primarily in Europe. Deeply resourced sector teams focus on specific sub-sectors and investment themes to identify companies occupying an established position within a niche, and which have the potential to grow faster than their market, create employment and become the leader in their industry. Hg’s dedicated operations innovation team provides practical support to management teams to help them realise their growth ambitions. Based in London and Munich, Hg has funds under management of c. £10 billion serving some of the world’s leading institutional and private investors. For further details, please see www.hgcapital.com

July 9, 2018 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 5 blogs containing over 11,000 articles with John having written over 5500 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 18 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

BaseHealth Raises $8.5 Million in Series C Funding

Company uses predictive analytics to uncover rising risk patients within a population

Sunnyvale, California: Oct. 18, 2017 – BaseHealth, the creator of the first predictive, evidence-based, and data-driven population health management solution, today announced that it has received an overall investment of $8.5 million, including $2.5 million from lead investor HBM Healthcare Investments (SIX HBMN), a listed healthcare investment company with net assets over $1 billion.

The investment will be used to further develop BaseHealth’s analytics engine, which is based on peer-reviewed medical literature, curated by physicians and scientists, and enhanced with laboratory, biometric, social, family history and behavioral data. BaseHealth supplements this with retrospective claims and ICD data. The data is then passed through the analytics engine, which uses machine learning and artificial intelligence (AI) to assess patient risk for 43 possible disease threats.

BaseHealth’s approach to population health and value-based care enables healthcare professionals to improve care and reduce the per capita cost of healthcare by identifying the rising unknown risk within their patient population, so they can intervene to both prevent diseases before they start and control them before it’s too late. The “Invisible Patient” is how BaseHealth refers to these individuals. With the right medical intervention at the right time, their healthcare trajectory can be improved.

“Healthcare systems have a lot of data and yet they still have a hard time finding these patients, making it hard to respond proactively to patient care needs,” said Jason Pyle, CEO, BaseHealth. “Our system enables healthcare professionals to assess the unknown risk that exists within their patient population and provide access and critical care needed to both improve our overall population’s health and improve the individual patient’s experience with the healthcare system.”

HBM Healthcare Investments has a track-record of over 100 biopharma and healthcare investments that have resulted in significant value creation by more than 50 trade sales and IPOs since inception.

“We look for companies that are at an advanced stage of development, that are closely tracked and actively guided on their strategic direction. We see a lot of potential in the BaseHealth model in addressing improvements in patient care and controlling costs in the healthcare system,” said Dr. Andreas Wicki, CEO, HBM Healthcare Investments.

About BaseHealth

BaseHealth is the comprehensive predictive analytics company for population health management. The company’s proprietary platform leverages machine learning to sift through millions of medical journals and patient records curated by scientists and physicians to offer healthcare providers the ability to identify patients with underlying risks for 43 chronic diseases and prevent costly treatments before they’re needed. At BaseHealth, we take the guesswork out of risk and population health management and put science in the driver’s seat.

BaseHealth was founded in 2011 by an interdisciplinary team of leading clinical geneticists, healthcare executives, software engineers, and physicians. Learn more at basehealth.com.

October 18, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 5 blogs containing over 11,000 articles with John having written over 5500 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 18 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Siemens Healthineers Supports Population Health Management with Planned Acquisition of Medicalis

  • Siemens Healthineers has signed an agreement to acquire Medicalis Corporation to expand Population Health Management portfolio
  • Medicalis’ expertise and solutions provide workflow orchestration and clinical decision support to health systems
  • Offerings expected to deliver desired service levels at lower costs while improving quality and productivity for healthcare providers

Siemens Healthineers plans to expand its Population Health Management (PHM) portfolio with the acquisition of Medicalis Corporation based in San Francisco and Kitchener, Ontario.  Medicalis is a leading provider of Clinical Decision Support (CDS) Solutions at the point of order entry, Imaging Workflow (IW) management, and Referral Management (RM). By incorporating these offerings into its PHM portfolio, Siemens Healthineers will enable healthcare providers to effectively bridge between PHM at the health system level and at the departmental level.  With an expanded focus on PHM, as well as a new name that underlines the company’s pioneering spirit and engineering expertise, Siemens Healthineers—the separately managed healthcare business of Siemens AG—is helping healthcare providers worldwide meet current challenges and excel in their respective environments.

“The mission of Siemens Healthineers is to be the trusted partner enabling health systems and healthcare providers worldwide to improve medical outcomes and reduce costs,” says Matthias Platsch, Head of Services, Siemens Healthineers. “The addition of Medicalis’ technology solutions to the Siemens Healthineers portfolio complements and supports our offerings in Population Health Management and Value-Based Healthcare, a key priority for our ongoing expansion through our Services business.”

The newly-acquired Population Health Management portfolio will extend the Siemens Healthineers strategy for Value-Based Healthcare across the health system enterprise and hospital departmental levels:

  • Clinical Decision Support provides the mechanism, as defined under the Protecting Access to Medicare Act of 2014 (PAMA), to check appropriateness of imaging orders and enables healthcare providers to define and evolve their standard of care, according to their appropriate use criteria (AUC), based on evidence and best practice. Today, 20%–30% of high-tech imaging procedures fail to provide information that improves patient welfare and, therefore, may represent, at least in part, unnecessary imaging services.
  • Imaging Workflow orchestrates the interpreting physician desktop, streamlining workflow, and standardization of diagnostic pathways for high-impact disease states. It ensures the right specialist, the right tools, a timely read, and prevention of care gaps.
  • Referral Management helps to avoid breaks in care by providing simple appointment scheduling tools, which help a patient schedule examinations in their network. This avoids leakage of patient information to another health system, which breaks communication and causes lost revenue.

In the short term, the solutions developed by Medicalis are expected to address the immediate need for consolidating providers to orchestrate and standardize their imaging workflow and to achieve compliance with the Protecting Access to Medicare Act of 2014, expected to become effective on January 1, 2018, which mandates consultation of appropriateness CDS at the point of order for certain advanced imaging tests. Siemens Healthineers believes these solutions will enable providers to achieve PAMA compliance while retaining control over the content, allowing them to move beyond simple compliance towards truly establishing an evolving standard of care based on evidence and direct health system experience.

“The acquisition of Medicalis will allow us to offer healthcare providers a powerful solution to define, implement, monitor, and evolve their own standard of care for their diagnostic service line,” says Robert Taylor, Head of Digital Services Population Health Management, Digital Health Services, Siemens Healthineers.  “We are excited to support our customers with these innovative tools to remove the variability from key high-impact disease states, to create standardized diagnostic pathways which enhance outcomes, control costs, and when combined with intelligent referral management, improve the patient experience overall.”

The solutions developed by Medicalis allow networks of hospitals (Health Systems/Integrated Delivery Networks) to improve physician productivity, manage patient referrals, and scheduling to enhance the relationship with the patient and ensure clinically appropriate imaging and tests to reduce inappropriate utilization.  Currently, seven of the top 25 Health Systems from Massachusetts to California use solutions developed by Medicalis to increase the quality of care they offer to patients.

“We are eager to be joining Siemens Healthineers and believe that this is a strong fit for our company because of our shared values and pioneering heritage,” says Oran Muduroglu, CEO of Medicalis Corporation. “With Siemens Healthineers, we will be able to broaden the context of our decision support, workflow, and referral management to utilize the full spectrum of diagnostic and therapeutic areas in which Siemens Healthineers operates, to address care gaps, streamline workflow, and help improve the overall experience of healthcare.”

The agreement to acquire the San Francisco, CA, USA and Kitchener, ON, Canada-based company by Siemens Healthineers was signed in April 2017.  Terms of the transaction are not disclosed.  The closing of the acquisition is subject to customary closing conditions.

 

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today’s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers.

In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and net income of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.

April 19, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 5 blogs containing over 11,000 articles with John having written over 5500 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 18 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

CareSkore Releases Industry’s First Population Health Management as a ServiceTM

PHMaaSTM Provides 3rd-party Apps Full Access to Complete Suite of Machine-learning Analytics through API

Mountain View, CA – February 9, 2017CareSkore, the leader in end-to-end personalized population health management, announced today the release of its Population Health Management as a ServiceTM (PHMaaSTM), providing direct access to its extensive machine-learning analytics engine to 3rd-party applications through an API.

“PHMaaS completely changes the game for how organizations adopt population health management,” said Jaspinder Grewal, CEO of CareSkore.  “We have too many proprietary application interfaces in health care.  PHMaaS allows us to provide insights within existing applications that are already part of user workflows.  Now patient-specific clinical, financial, and behavioral risk stratification is as simple as making a seamless API call from within your existing EHR and other applications.”

CareSkore’s personalized population health management SaaS platform incorporates advanced real-time analytics and innovative AI-based patient engagement to deliver optimized quality of care.  CareSkore PHMaaS provides existing health care IT systems seamless access to its machine-learning-based, real-time analytics engine, aptly called Zeus, through a simple API call.  Now EHRs, middleware platforms, enterprise data warehouses, clinical information networks, and health information exchanges that are already deployed can provide Zeus with real-time internal clinical and claims data and have Zeus augment that with external intelligence specific to every patient on things like demographics and socio-economic characteristics.  The output is patient-specific predictive analytics with a focus on how providers can quickly operationalize those insights. 

Traditional analytics typically achieve accuracy between 60 and 70%, while CareSkore can deliver greater than 90% accuracy to help create a full view of each patient.  This superior capability is driving rapid growth, with customers increasing 1,000% and headcount rising 12x in 2016.  By the end of 2017, CareSkore expects to be deployed in hundreds of locations.

“CareSkore has dramatically simplified the implementation of advanced patient-specific analytics,” said Rohit Arora, Professor and Chairman of Cardiovascular Medicine, Chicago Medical School.  “Access through and integration with existing EHR and other apps significantly lowers the barriers to adoption and deployment.”

CareSkore will exhibit at HIMSS 17 in Orlando in booth 1623 from February 20-22, 2017. To schedule a demo of the PHMaaS solution, go tohttp://resources.careskore.com/himss-2017.

About CareSkore

CareSkore is the leading provider of personalized population health management, leveraging machine-learning to generate real-time predictive and prescriptive analytics to understand each patient you are managing, what you are managing them for, and how you are/should be managing them.  CareSkore’s AI-enhanced post-discharged engagement reduces risk of patient behaviors that could lead to poorer outcomes.  CareSkore’s end-to-end patient care management platform ensures quality results and maximum revenue with value-based contracts.

February 9, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 5 blogs containing over 11,000 articles with John having written over 5500 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 18 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Philips Acquires Wellcentive

AMSTERDAM–(BUSINESS WIRE)–Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has signed an agreement to acquire Wellcentive, a leading US-based provider of population health management software solutions. Financial details of the transaction will not be disclosed.

In population health management, Philips already offers enterprise telehealth, home monitoring, personal emergency response systems (PERS) and personal health services that address multiple groups within a population from intensive ambulatory care for high-risk patients to prevention and personal health programs for the general population. Wellcentive complements Philips’ portfolio with cloud-based IT solutions to import, aggregate and analyze clinical, claims and financial data across hospital and health systems to help care providers deliver coordinated care that meets new healthcare quality requirements and reimbursement models.

Upon completion of the transaction, which is expected later today, Wellcentive and its employees will become part of the Population Health Management business group within Philips. Tom Zajac, CEO of Wellcentive and an experienced healthcare industry leader, will be appointed to lead this business group.

“With this strategic acquisition, we will strengthen our Population Health Management business and its leadership, as health systems gradually shift from volume to value-based care, and provide more preventative and chronic care services outside of the hospital,” said Jeroen Tas, Philips’ CEO Connected Care & Health Informatics. “Our sweet spot is at the point of care as we give consumers, patients, care teams and clinicians the tools, such as remote monitoring solutions and therapy devices, to optimize care. Wellcentive’s solutions will provide our customers with the ability to collect data from large populations, detect patterns, assess risks and then deploy care programs tailored to the needs of specific groups.”

“Over the past 11 years, the Wellcentive team has focused on delivering data-driven clinical, financial, and human outcomes for our customers as they provide care management for more than 30 million patients,” said Tom Zajac, CEO of Wellcentive. “Combining forces with Philips and its broad portfolio of health technologies and global reach will create a great foundation to accelerate growth in connected care – from healthy living and prevention, to diagnosis, treatment and home care – enabling consumers, providers and health organizations to benefit from our combined, stronger offering in population health management.”

Wellcentive’s applications will be integrated in the Philips HealthSuite cloud, the company’s digital enabler for the next generation of connected health solutions. One example of Philips’ existing care programs for population health management is the Intensive Ambulatory Care (eIAC) program: this combines telehealth technologies and population health management software to help care teams monitor and coach patients at home. It aims to improve patient outcomes, care team efficiency, and prevent patients from entering the hospital, where costs are significantly higher.

Founded in 2005 and headquartered in Atlanta, Georgia, Wellcentive employs approximately 115 employees. The company has a strong customer base in the US.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

July 20, 2016 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 5 blogs containing over 11,000 articles with John having written over 5500 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 18 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.